EUVIMEDEUVIMED entdecken
Crossref

To Compare the Effects of Remimazolam and Dexmedetomidine with respect to the QoR-40 Score of Patients who have undergone FESS

Chandrala Kishan Kishorbhai, Rahul Datta Roy, Bhimani Heta Shaileshbhai, Swapan Debbarma

INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE · 2025

DOI: 10.25258/ijpqa.16.1.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE, 2025. Verfasst von Chandrala Kishan Kishorbhai und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic Rhinosinusitis (CRS) is a common illness that reduces a patient's quality of life. When medication is inadequate, Functional Endoscopic Sinus Surgery (FESS) can improve quality of life and symptoms of sickness both temporarily and permanently. However, 65% of patients with FESS experienced mild to severe pain on postoperative Day 1 (POD1). Although Remimazolam is a new ultrashort-acting benzodiazepine with minimal side effects and hemodynamic stability, it is rapidly becoming a sedative-anesthetic in clinical practice. Remimazolam have anti-inflammatory, immunomodulatory and analgesic properties.

Aim

The current study aims to compare the effects of remimazolam and dexmedetomidine with respect to the QoR-40 score of patients who have undergone FESS Method: GMERS Medical College in Junagadh, Gujarat, was the place to conduct a single-blind, randomized controlled clinical trial for this investigation. The university's ethical committee accepted the study, and regular procedures were followed to ensure the research's validity. A 1:1:1 random assignment was used to place the 120 eligible patients in Group R, Group D, or Group C. Age between 18 and 65 years, synchronous sinonasal symptoms that have persisted for more than 12 weeks, sinusitis as shown by a sinus computerized tomography (CT) scan, physical status I or II as defined by the American Society of Anesthesiologists (ASA), and a scheduled elective FESS were the criteria used to prospectively enroll CRS subjects.

Results

QoR-40 scores of Groups R (154.5, 152.0–159.0) and D (155.0, 154.8–159.3) had lower QoR-40 (median, IQR) scores overall at POD1 than Group C (139.0, 136.8–142.0) (P < 0.001). The overall QoR-40 score did not differ significantly between Groups R and D. Moreover, the emotional intelligence scores on POD1, Groups R and D had lower state, physical comfort, and pain dimensions than Group C (P < 0.005). Moreover, the maximal VAS pain score was lower in the PACU and ward in Groups R and D than in Group C (P < 0.001). The RASS score was lower upon PACU arrival in Groups R and D than in Group C (P < 0.001).

Conclusion

From the analysis of study, it has been concluded that after FESS, remimazolam and dexmedetomidine may lower the intensity of pain and enhance the quality of recovery. Remimazolam's efficacy and safety are on par with dexmedetomidine

Zitieren

APA

Kishorbhai, C. K., Roy, R. D., Shaileshbhai, B. H., & Debbarma, S. (2025). To Compare the Effects of Remimazolam and Dexmedetomidine with respect to the QoR-40 Score of Patients who have undergone FESS. INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE. https://doi.org/10.25258/ijpqa.16.1.5

Vancouver

Kishorbhai CK, Roy RD, Shaileshbhai BH, Debbarma S. To Compare the Effects of Remimazolam and Dexmedetomidine with respect to the QoR-40 Score of Patients who have undergone FESS. INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE. 2025. doi:10.25258/ijpqa.16.1.5

BibTeX
@article{Kishorbhai2025,
  author = {Kishorbhai, Chandrala Kishan and Roy, Rahul Datta and Shaileshbhai, Bhimani Heta and Debbarma, Swapan},
  title = {To Compare the Effects of Remimazolam and Dexmedetomidine with respect to the QoR-40 Score of Patients who have undergone FESS},
  journal = {INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE},
  year = {2025},
  doi = {10.25258/ijpqa.16.1.5}
}
Kostenlos starten →